HomeComparePBAX vs MRK

PBAX vs MRK: Dividend Comparison 2026

PBAX yields 34.19% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PBAX wins by $111.3K in total portfolio value
10 years
PBAX
PBAX
● Live price
34.19%
Share price
$5.85
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$168.1K
Annual income
$24,882.33
Full PBAX calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — PBAX vs MRK

📍 PBAX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPBAXMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PBAX + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PBAX pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PBAX
Annual income on $10K today (after 15% tax)
$2,905.98/yr
After 10yr DRIP, annual income (after tax)
$21,149.98/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, PBAX beats the other by $12,821.57/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PBAX + MRK for your $10,000?

PBAX: 50%MRK: 50%
100% MRK50/50100% PBAX
Portfolio after 10yr
$112.4K
Annual income
$17,340.23/yr
Blended yield
15.43%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

PBAX
No analyst data
Altman Z
-49.5
Piotroski
3/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PBAX buys
0
MRK buys
0
No recent congressional trades found for PBAX or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPBAXMRK
Forward yield34.19%2.76%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$168.1K$56.8K
Annual income after 10y$24,882.33$9,798.13
Total dividends collected$120.3K$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: PBAX vs MRK ($10,000, DRIP)

YearPBAX PortfolioPBAX Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$14,119$3,418.80$11,206$366.19+$2.9KPBAX
2$19,618$4,511.16$12,650$502.35+$7.0KPBAX
3$26,850$5,858.24$14,407$694.19+$12.4KPBAX
4$36,222$7,493.14$16,585$967.82+$19.6KPBAX
5$48,205$9,447.49$19,342$1,363.89+$28.9KPBAX
6$63,330$11,750.38$22,913$1,947.19+$40.4KPBAX
7$82,191$14,427.22$27,662$2,823.89+$54.5KPBAX
8$105,443$17,498.86$34,159$4,173.35+$71.3KPBAX
9$133,805$20,980.74$43,337$6,308.80+$90.5KPBAX
10$168,053$24,882.33$56,776$9,798.13+$111.3KPBAX

PBAX vs MRK: Complete Analysis 2026

PBAXStock

Phoenix Biotech Acquisition Corp. does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It engages in identifying and acquiring a business that focuses on the healthcare or healthcare related industries in the United States and Europe. The company was incorporated in 2021 and is based in Oakland, California.

Full PBAX Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this PBAX vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PBAX vs SCHDPBAX vs JEPIPBAX vs OPBAX vs KOPBAX vs MAINPBAX vs JNJPBAX vs ABBVPBAX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.